Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05507814
Other study ID # VT IRB #22-529
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 30, 2022
Est. completion date March 31, 2025

Study information

Verified date April 2024
Source Virginia Polytechnic Institute and State University
Contact Kirstin Gatchalian
Phone 540-526-2071
Email kmgatch@vt.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective is to test the theory of Reinforcer Pathology via manipulation of the temporal window with successive Episodic Future Thinking generation in individuals with cocaine use disorder.


Description:

Adults with cocaine use disorder will be randomly assigned to experimental or control groups, stratified by polydrug use disorder, SES, and sex. The experimental group will compare episodic future thinking (EFT) to control episodic thinking (CET). The study procedures will include a baseline session (S1) and a 4-week intervention period where participants will return to the lab three times a week. Participants will generate new EFT and CET events at approximately weekly intervals. The EFT or CET events will be texted to them twice daily with urine samples obtained thrice-weekly. To probe resistance to disruption, both groups will receive stress-inducing probes that shorten the temporal window after the first and last cue generation. During the first assessment visit (S2), participants will be randomized with stratification to generate either episodic future thinking (EFT) or control episodic thinking (CET) events and will undergo neuroimaging procedures. At the following session in S3, participants will be randomized to receive one of two stress probes (counterbalanced) or their respective control. Participants will be exposed to a stress probe or control at S3 and the corresponding narrative at the next visit, S4. S5 and S6 will begin with participants generating new EFT/CET events that will be used for that session and the following two sessions. S7, like S2, will begin with EFT/CET event generation and neuroimaging procedures. During the final two sessions (S8, S9), participants will be exposed to the other stress probe and control that they did not see during S3/S4.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date March 31, 2025
Est. primary completion date March 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. demonstrate recent cocaine use and CUD (use in last month, DSM-5 for CUD > 4) 2. be 18 years of age or older 3. have a desire to quit or cut down on their cocaine use, but do not have proximate plans to enroll in treatment for CUD during the study period Exclusion Criteria: 1. meeting moderate to severe DSM-5 criteria for opioid use disorder 2. having a current diagnosis of any psychotic disorder 3. having a history of seizure disorders or traumatic brain injury 4. having any contraindication for participation in the MRI sessions

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Episodic Future Thinking (EFT)
Participants will generate descriptions of vivid positive future events.
Control Episodic Thinking
Participants will generate descriptions of vivid positive future events.

Locations

Country Name City State
United States Fralin Biomedical Research Institute at VTC Roanoke Virginia

Sponsors (3)

Lead Sponsor Collaborator
Virginia Polytechnic Institute and State University Arizona State University, Carilion Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Delay Discounting Delay discounting tasks provide a measure of the temporal window and examine the devaluation of awards as a function of the delay to the receipt. These computerized assessments provide participants with hypothetical choices between smaller amounts of a reward available immediately and a larger amount of a reward after a range of delays (1 day-25 years). Discounting rates will be measured using adjusting amount delay discounting and minute delay discounting tasks. Change in discounting rates will be compared within-subjects across sessions and between groups. Over four-weeks of participation (Weekly for four weeks)
Primary Change in Cocaine Demand Intensity and elasticity of cocaine demand will be determined from a cocaine demand curve via a Cocaine Purchase Task (CPT). Change in cocaine demand will be compared within-subjects across sessions and between groups. Over four weeks of participation (Weekly for four weeks)
Primary Cocaine Craving The Desires for Drug Questionnaire (DDQ) will be used to assess instant craving for cocaine. Change in cocaine craving will be compared within-subjects across sessions and between groups. Over four weeks of participation (Weekly for four weeks)
Primary Neural activation during fMRI delay discounting task Brain maps will be compared between groups and time points. Over four weeks of participation (Baseline, Week 1, Week 4)
Primary Neural activation during fMRI cocaine purchase task Brain maps will be compared between groups and time points. Over four weeks of participation (Baseline, Week 1, Week 4)
Secondary Daily Cocaine Use Daily cocaine use will be assessed via the daily Ecological Momentary Assessments (EMAs). Change in daily cocaine use will be compared within-subjects across the study duration and between groups. Over four weeks of participation
Secondary Cocaine Urinalysis Cocaine urinalysis will be measured from the urinalysis collected at sessions and retention check-ins. Change in cocaine urinalysis will be compared within-subjects across the study duration and between groups. Over four weeks of participation
See also
  Status Clinical Trial Phase
Completed NCT03538548 - Treatment Outcome in CBT for Cocaine Use N/A
Recruiting NCT04994821 - tDCS to Reduce Craving in Cocaine Addiction- Phase 2 Study Phase 2
Not yet recruiting NCT06050304 - CRACK-TARGET 1: ÉTUDE DESCRIPTIVE DE LA SENSIBILISATION COMPORTEMENTALE OBSERVÉE et ATTENTES
Completed NCT02233647 - Phendimetrazine and Cocaine Early Phase 1
Completed NCT02239913 - Topiramate-Phentermine Combinations for Cocaine Dependence Phase 1
Recruiting NCT04927143 - Encouraging Abstinence Behavior in a Drug Epidemic Phase 2
Completed NCT03224546 - Cocaine Use Reduction and Health N/A
Recruiting NCT03656653 - Imagery-based Coping for Cocaine Use Disorder N/A
Completed NCT03348384 - [11C]NOP-1A and Cocaine Use Disorders Early Phase 1
Recruiting NCT05019430 - Cocaine and Zolmitriptan Early Phase 1
Recruiting NCT03344419 - Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders Phase 3
Active, not recruiting NCT03799341 - Neurocognitive Factors in Substance Use Treatment Response: The Ways of Rewarding Abstinence Project N/A
Completed NCT02798627 - Trial Of NS2359 For The Treatment of Cocaine Dependence Phase 2
Completed NCT02785406 - Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use Phase 2
Completed NCT02444208 - A Feasibility Trial for Inhibitory-Control Training to Reduce Cocaine Use N/A
Recruiting NCT05902819 - Reconsolidation Blockade of Intrusive Trauma- and Cocaine-related Memories N/A
Recruiting NCT05521854 - Contingency Management for Drug Use: Does Age Matter? N/A
Recruiting NCT05833529 - Innovative Cognitive and Behavioral Psychotherapy for Cocaine Use Disorder N/A
Completed NCT05557149 - Virtual Reality Exposure and Respiratory Relaxation-Based Coping With Cocaine Craving in Cocaine Users N/A
Terminated NCT04826133 - Vitamin D and Cocaine Administration Early Phase 1